News & Events

• April 7, 2022
  

  Doctor With Rare Disease And No Answers Decides To Find His Own Cure

  David Fajgenbaum was diagnosed with Castleman disease as a medical student. In Chasing My Cure, he recounts crowd-sourcing his own treatment with a global network of doctors, scientists and patients.

• April 7, 2022
  

  Castleman’s Disease: Behind the Mystery of Rare Disease

  We’re going Behind the Mystery of two rare diseases: Castleman disease and chondrosarcoma.

  There are no effective treatment options for people with unresectable or metastatic chondrosarcoma despite many attempts by multiple pharmaceutical companies over the past few decades. Inhibrx, a clinical-stage biotechnology company, is dedicated to helping people with life-threatening conditions. They are developing a therapeutic option for chondrosarcoma called INBRX-109, which is currently in clinical trials.

• November 9, 2021
  

  C-Path Joins New Coalition to Improve Patient Care and Address Unmet Medical Needs through Community-Level Clinical Trials

  WASHINGTON and TUCSON, Ariz., November 9, 2021 — Launching today, the Advancing Clinical Trials at the Point of Care (ACT@POC) Coalition will generate quality clinical research evidence in real time to better evaluate treatments and therapeutics, including those to treat COVID-19. The Coalition will engage a broader, more diverse group of patients and providers and develop digital health tools that make clinical trials simpler to run and more accessible to patients.

• March 31, 2021
  

  Cures Within Reach Names CURE ID as 2021 Patient Impact Awardee

    Cures Within Reach, a global nonprofit leading the use of repurposing research to help improve patients’ lives, has awarded CURE ID at the FDA and NCATS/NIH as the recipient of the 2021 Golan Christie Taglia Patient Impact Philanthropy Award part of its 2021 Patient Impact Award recipients of the Global Health Repurposing Awards. C-Path’s Cure Drug Repurposing Collaboratory (CDRC),...
• February 4, 2021
  

  C-Path Appoints Co-Directors to CURE Drug Repurposing Collaboratory Advisory Committee

  TUCSON, Ariz., February 4, 2021 — Critical Path Institute (C-Path) today has announced the appointments of David Fajgenbaum, M.D., M.S., M.B.A., and Marco Schito, Ph.D., as co-directors of the advisory committee for C-Path’s CURE Drug Repurposing Collaboratory (CDRC) program.